AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
bromhexine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| mucolytic, bromhexine derivatives | 402 | 3572-43-8 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A mucolytic agent used in the treatment of respiratory disorders associated with viscid or excessive mucus. (From Martindale, The Extra Pharmacopoeia, 30th ed, p744)
|
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 24 | mg | O |
| 24 | mg | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 77.50 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AKT1,AKT2,AKT3,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK2,JAK3,MAP2K6,MAP3K14,MAP3K21,MAP3K7,MAPK10,MAPK12,MAPK7,MAPK9,MAPKAPK2,MARK4,MET,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ZAP70 | 58 | |||
| kinase-selectivity-class | AXL,CDK4,EIF2AK3,GRK2,STK33,TEK,TTK | 7 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pneumonia aspiration | 122.64 | 32.92 | 43 | 2044 | 40897 | 90585463 |
| Coma | 79.55 | 32.92 | 37 | 2050 | 72595 | 90553765 |
| Vaginal flatulence | 73.56 | 32.92 | 22 | 2065 | 12616 | 90613744 |
| Underdose | 70.15 | 32.92 | 31 | 2056 | 53986 | 90572374 |
| Female genital tract fistula | 70.08 | 32.92 | 23 | 2064 | 17845 | 90608515 |
| Proctitis | 69.48 | 32.92 | 22 | 2065 | 15237 | 90611123 |
| Radiculopathy | 65.31 | 32.92 | 22 | 2065 | 18483 | 90607877 |
| Vaginal discharge | 64.22 | 32.92 | 22 | 2065 | 19442 | 90606918 |
| Chronic sinusitis | 63.62 | 32.92 | 23 | 2064 | 23779 | 90602581 |
| Nephrosclerosis | 61.26 | 32.92 | 12 | 2075 | 1157 | 90625203 |
| Paraesthesia oral | 60.72 | 32.92 | 24 | 2063 | 31635 | 90594725 |
| Renal tubular atrophy | 57.59 | 32.92 | 11 | 2076 | 929 | 90625431 |
| Procedural pain | 56.07 | 32.92 | 23 | 2064 | 33337 | 90593023 |
| Gastrooesophageal reflux disease | 55.63 | 32.92 | 39 | 2048 | 166298 | 90460062 |
| Oral candidiasis | 51.39 | 32.92 | 22 | 2065 | 35433 | 90590927 |
| Macular degeneration | 49.94 | 32.92 | 22 | 2065 | 37948 | 90588412 |
| Somnolence | 49.80 | 32.92 | 40 | 2047 | 209044 | 90417316 |
| Kidney fibrosis | 48.10 | 32.92 | 11 | 2076 | 2223 | 90624137 |
| Tubulointerstitial nephritis | 47.84 | 32.92 | 19 | 2068 | 25324 | 90601036 |
| Frequent bowel movements | 44.31 | 32.92 | 23 | 2064 | 56912 | 90569448 |
| Colitis ulcerative | 43.08 | 32.92 | 23 | 2064 | 60243 | 90566117 |
| Haematochezia | 42.26 | 32.92 | 24 | 2063 | 70889 | 90555471 |
| Colitis | 39.88 | 32.92 | 23 | 2064 | 69919 | 90556441 |
| Rectal haemorrhage | 38.82 | 32.92 | 24 | 2063 | 82720 | 90543640 |
| Constipation | 37.85 | 32.92 | 39 | 2048 | 280356 | 90346004 |
| Anaemia | 37.07 | 32.92 | 43 | 2044 | 352759 | 90273601 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Central nervous system mass | 64.69 | 30.85 | 13 | 1651 | 838 | 42618833 |
| Wall motion score index abnormal | 64.63 | 30.85 | 13 | 1651 | 842 | 42618829 |
| Airway remodelling | 63.96 | 30.85 | 13 | 1651 | 887 | 42618784 |
| Cardiac septal defect | 63.12 | 30.85 | 13 | 1651 | 947 | 42618724 |
| Atopy | 62.92 | 30.85 | 13 | 1651 | 962 | 42618709 |
| Eosinophilic myocarditis | 58.49 | 30.85 | 13 | 1651 | 1360 | 42618311 |
| Microangiopathy | 55.86 | 30.85 | 13 | 1651 | 1669 | 42618002 |
| Pneumonia | 54.63 | 30.85 | 74 | 1590 | 422075 | 42197596 |
| Chronic sinusitis | 51.44 | 30.85 | 14 | 1650 | 3378 | 42616293 |
| Eosinophilic pneumonia | 46.42 | 30.85 | 14 | 1650 | 4860 | 42614811 |
| Eosinophil count decreased | 46.13 | 30.85 | 13 | 1651 | 3563 | 42616108 |
| Blood immunoglobulin E increased | 45.95 | 30.85 | 13 | 1651 | 3612 | 42616059 |
| Nasal polyps | 45.18 | 30.85 | 13 | 1651 | 3838 | 42615833 |
| Ventricular hypokinesia | 37.74 | 30.85 | 13 | 1651 | 6871 | 42612800 |
| Eosinophil count increased | 35.56 | 30.85 | 14 | 1650 | 10749 | 42608922 |
| Respiratory tract infection | 31.81 | 30.85 | 17 | 1647 | 26305 | 42593366 |
| Respiratory symptom | 31.69 | 30.85 | 13 | 1651 | 11093 | 42608578 |
| Eosinophilic granulomatosis with polyangiitis | 31.24 | 30.85 | 12 | 1652 | 8626 | 42611045 |
| Lacrimation increased | 30.97 | 30.85 | 13 | 1651 | 11745 | 42607926 |
| Pneumonia aspiration | 30.92 | 30.85 | 21 | 1643 | 50057 | 42569614 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Pneumonia aspiration | 132.24 | 25.84 | 62 | 3819 | 81171 | 110504247 |
| Chronic sinusitis | 98.64 | 25.84 | 36 | 3845 | 25048 | 110560370 |
| Vaginal flatulence | 65.25 | 25.84 | 22 | 3859 | 12122 | 110573296 |
| Female genital tract fistula | 62.30 | 25.84 | 23 | 3858 | 16496 | 110568922 |
| Pneumonia | 61.73 | 25.84 | 110 | 3771 | 876604 | 109708814 |
| Central nervous system mass | 60.24 | 25.84 | 12 | 3869 | 822 | 110584596 |
| Wall motion score index abnormal | 60.14 | 25.84 | 12 | 3869 | 829 | 110584589 |
| Airway remodelling | 58.78 | 25.84 | 12 | 3869 | 930 | 110584488 |
| Radiculopathy | 58.78 | 25.84 | 23 | 3858 | 19313 | 110566105 |
| Cardiac septal defect | 58.30 | 25.84 | 12 | 3869 | 969 | 110584449 |
| Proctitis | 58.11 | 25.84 | 22 | 3859 | 16905 | 110568513 |
| Vaginal discharge | 56.91 | 25.84 | 22 | 3859 | 17886 | 110567532 |
| Atopy | 56.36 | 25.84 | 12 | 3869 | 1142 | 110584276 |
| Underdose | 55.58 | 25.84 | 32 | 3849 | 63522 | 110521896 |
| Macular degeneration | 52.86 | 25.84 | 22 | 3859 | 21637 | 110563781 |
| Coma | 52.80 | 25.84 | 39 | 3842 | 117830 | 110467588 |
| Nephrosclerosis | 49.66 | 25.84 | 12 | 3869 | 2009 | 110583409 |
| Paraesthesia oral | 49.52 | 25.84 | 24 | 3857 | 33647 | 110551771 |
| Eosinophilic myocarditis | 49.29 | 25.84 | 12 | 3869 | 2073 | 110583345 |
| Procedural pain | 45.33 | 25.84 | 23 | 3858 | 35542 | 110549876 |
| Microangiopathy | 45.07 | 25.84 | 12 | 3869 | 2960 | 110582458 |
| Renal tubular atrophy | 43.27 | 25.84 | 11 | 3870 | 2265 | 110583153 |
| Eosinophilic pneumonia | 42.43 | 25.84 | 14 | 3867 | 7213 | 110578205 |
| Gastrooesophageal reflux disease | 42.16 | 25.84 | 41 | 3840 | 179935 | 110405483 |
| Oral candidiasis | 37.69 | 25.84 | 22 | 3859 | 44738 | 110540680 |
| Constipation | 37.55 | 25.84 | 54 | 3827 | 357732 | 110227686 |
| Eosinophil count decreased | 36.71 | 25.84 | 12 | 3869 | 6006 | 110579412 |
| Kidney fibrosis | 36.12 | 25.84 | 11 | 3870 | 4381 | 110581037 |
| Colitis ulcerative | 35.53 | 25.84 | 26 | 3855 | 77337 | 110508081 |
| Blood immunoglobulin E increased | 34.15 | 25.84 | 12 | 3869 | 7470 | 110577948 |
| Eosinophil count increased | 30.92 | 25.84 | 15 | 3866 | 21043 | 110564375 |
| Nasal polyps | 30.83 | 25.84 | 13 | 3868 | 13187 | 110572231 |
| Frequent bowel movements | 30.55 | 25.84 | 23 | 3858 | 71367 | 110514051 |
| Ventricular hypokinesia | 29.42 | 25.84 | 12 | 3869 | 11202 | 110574216 |
| Tubulointerstitial nephritis | 28.97 | 25.84 | 20 | 3861 | 54264 | 110531154 |
| Pyrexia | 28.25 | 25.84 | 82 | 3799 | 898183 | 109687235 |
| Upper respiratory tract inflammation | 27.81 | 25.84 | 9 | 3872 | 4362 | 110581056 |
| Colitis | 27.16 | 25.84 | 25 | 3856 | 102298 | 110483120 |
| Somnolence | 27.04 | 25.84 | 42 | 3839 | 297407 | 110288011 |
| Eosinophilic granulomatosis with polyangiitis | 26.56 | 25.84 | 11 | 3870 | 10675 | 110574743 |
| Haematochezia | 26.43 | 25.84 | 26 | 3855 | 115498 | 110469920 |
| Respiratory symptom | 26.11 | 25.84 | 12 | 3869 | 14933 | 110570485 |
| Hepatic function abnormal | 26.03 | 25.84 | 23 | 3858 | 89272 | 110496146 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | R05CB02 | RESPIRATORY SYSTEM COUGH AND COLD PREPARATIONS EXPECTORANTS, EXCL. COMBINATIONS WITH COUGH SUPPRESSANTS Mucolytics |
| MeSH PA | D005100 | Expectorants |
| MeSH PA | D019141 | Respiratory System Agents |
| CHEBI has role | CHEBI:77034 | mucolytic |
| CHEBI has role | CHEBI:22587 | antiviral agent |
| CHEBI has role | CHEBI:38068 | antimalarial |
Related Drugs by ATC class:
R05CB Mucolytics 13 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.16 | Basic |
| pKa2 | 0.87 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 7.60 | DRUG MATRIX | |||||
| Sodium-dependent serotonin transporter | Transporter | Ki | 5.95 | DRUG MATRIX | |||||
| Cytochrome P450 2D6 | Enzyme | IC50 | 6.71 | DRUG MATRIX | |||||
| Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 7.44 | DRUG MATRIX |
External reference:
| ID | Source |
|---|---|
| N0000166541 | NUI |
| D01778 | KEGG_DRUG |
| 1601 | RXNORM |
| C0006220 | UMLSCUI |
| CHEBI:77032 | CHEBI |
| CHEMBL253376 | ChEMBL_ID |
| DB09019 | DRUGBANK_ID |
| D001964 | MESH_DESCRIPTOR_UI |
| 2442 | PUBCHEM_CID |
| 11218 | IUPHAR_LIGAND_ID |
| 2584 | INN_ID |
| 611-75-6 | SECONDARY_CAS_RN |
| Q1J152VB1P | UNII |
| NOCODE | MMSL |
| 412102008 | SNOMEDCT_US |
| 708561003 | SNOMEDCT_US |
| 846647005 | SNOMEDCT_US |
| CHEMBL1319139 | ChEMBL_ID |
| 003678 | NDDF |
| 003679 | NDDF |
Pharmaceutical products:
None